You are here: Industry Insights > Zymeworks

News List

Zymeworks gets EC’s orphan drug designation for zanidatamab in patients with gastric cancer pharmaceutical-business-review
November 24, 2020
Zymeworks announced that the European Commission (EC) has granted Orphan Drug designation for zanidatamab, the company’s investigational HER2-targeted bispecific antibody, in patients with gastric cancer.
BeiGene doses first patient in phase 1b/2 trial of ZW25 in HER2-positive breast cancer and GEA pharmaceutical-business-review
April 06, 2020
Zymeworks announced that its partner, BeiGene has dosed the first patient in a two-arm Phase 1b/2 trial evaluating the former's HER2-targeted bispecific antibody ZW25 in combination with chemotherapy.
GSK expands bispecific antibodies deal with Zymeworks pharmaceutical-technology
May 22, 2019
GlaxoSmithKline (GSK) has expanded its licensing and collaboration agreement with Canadian biotechnology firm Zymeworks.
Daiichi selects oncology candidate built on Zymeworks’ Bispecific platform biospectrumasia
April 28, 2019
One of three bispecific immuno-oncology therapeutics being developed under the two companies’ collaboration agreements
Daiichi picks immuno-oncology bispecific, triggering payout to Zymeworks fiercebiotech
April 28, 2019
Daiichi Sankyo has selected the first immuno-oncology candidate under its deal with Zymeworks. The action sees Daiichi pay Zymeworks $3.5 million to license an asset based on its bispecific antibody platform.
Zymeworks and LEO Pharma Enter into Bispecific Antibody Licensing and Research Collaboration pharmafocusasia
December 04, 2018
Zymeworks Inc., a clinical-stage biopharmaceutical company developing multifunctional therapeutics, and LEO Pharma A/S, a global leader in medical dermatology.....
ProBioGen Announces Successful Bispecific GlymaxX® Development Project for Zymeworks b3cnewswire
November 10, 2018
The project met the primary goals for the bispecific antibody cell line, which were achieving high titers and bispecific purity and maintaining stability during scale-up. Zymeworks is continuing further process development and large-scale production.
Zymeworks could get up to $485M in expanded Daiichi I-O deal fiercebiotech
May 16, 2018
When Zymeworks and Daiichi Sankyo initially teamed up on bispecific antibodies in 2016, they kept the financial details under wraps.
Zymeworks, Celgene expand bispecific antibody partnership biospectrumasia
April 25, 2018
Zymeworks will receive an expansion fee of $164M and will be eligible to receive milestones plus royalties on all products as before.